A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

Inclusion Criteria:

• Participant must be ≥ 18 and ≤ 80 years of age at the time of signing the informedconsent.

• Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is definedas life-threatening organ dysfunction caused by a dysregulated host response toinfection.

• participants with suspected or documented origin of infection.

• Participants with coagulopathy defined by at least one of the following within 24hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hourswithout other known etiology. The platelet count after decrease should not be < 30,000/mm3.

• Participants must be receiving treatment in an ICU.

• Informed consent of capable participant or, in case of participant being incapableof giving informed consent, consent for study inclusion will be sought according toapplicable laws and regulations.

Exclusion Criteria:

• Clinically significant active bleeding; known bleeding disorder, history of majortraumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) orclinically significant gastrointestinal bleeding within last 6 months.

• Low platelets level or abnormal coagulation status due to any other reason thansepsis.

• Participants with indication for therapeutic dose of: anticoagulation (heparin,argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban,edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine,prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin

• Any active malignancy

• Pregnancy or breastfeeding.

• Chronic liver disease Child-Pugh Class C.

• Participants experienced major surgery or major trauma (intrathoracic,intra-abdominal, pelvic or femur) or surgery/trauma in any other area withpotentially clinically significant consequences due to bleeding within 28 daysbefore study drug administration.

• Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedicsurgery in spine within 6 months before study drug administration